Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies

References

• Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S01406736(20)30925-9.
   PubMed Web of Science ®Google Scholar
• To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):1809. doi:10.1186/14712458-12-204.
   Google Scholar
• Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMRA2032506.
   PubMed Web of Science ®Google Scholar
• 2021 GINA report, global strategy for asthma management and prevention (2021 update). Global initiative for asthma; Published 2021. [accessed 2022 Jul 20]. https://ginasthma.org/gina-reports/.
   Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1) doi:10.1002/14651858.CD003559.pub4.
   Web of Science ®Google Scholar
• McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–971. doi:10.1007/s40273-018-0658-x.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, Rajput Y. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23–32. doi:10.1080/03007995.2019.1660539/SUPPL_FILE/ICMO_A_1660539_SM0850.DOCX
   PubMed Web of Science ®Google Scholar
• Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872–881. doi:10.1080/02770903.2018.1500584.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kaur H, Choubey A, Popli A, Muthukumar M, Yoshisue H, Funakubo M, Ohta K. Cost-effectiveness analysis of omalizumab for severe allergic asthma in japan using real-world evidence. Value Health Reg Issues. 2022;27:41–48. doi:10.1016/j.vhri.2021
   PubMedGoogle Scholar
• van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Costeffectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–348. doi:10.3111/13696998.2012.756398.
   PubMedGoogle Scholar
• Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:10.1016/J.ANAI.2016.10.028.
   PubMed Web of Science ®Google Scholar
• Crespo C, Monleon A, Díaz W, Ríos M. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014;14:139. doi:10.1186/1471-2288-14-139.
   PubMed Web of Science ®Google Scholar
• Veettil SK, Syeed MS, Noviyan R, Thakkinstian A, Chaiyakunapruk N. Does metaanalysis of economic evaluations have the potential to play a role in healthcare decisionmaking in the United States? J Med Econ. 2022;25(1):750–754. doi:10.1080/13696998.2022.2083347.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Metaanalysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22:202. doi:10.1186/s12913022-07595-1.
   PubMed Web of Science ®Google Scholar
• WDI - The World by Income and Region. The World Bank [accessed 2022 Jul 20]. https://datatopics.worldbank.org/world-development-indicators/the-world-by-incomeandregion.html.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Andersson M, Janson C, Kristensen T, Szende A, Golam S. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden. J Med Econ. 2020;23(8):877–884. doi:10.1080/13696998.2020.1760285.
   PubMed Web of Science ®Google Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–153. doi:10.1111/J.13989995.2006.01310.X.
   PubMed Web of Science ®Google Scholar
• Buendia JA, Patiño DG, Cossio-Giraldo YE. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. J Asthma. 2022;59(10):2016–2023. doi:10.1080/02770903.2021.1984527.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Patiño DG, Lopez Moreno M. Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2022;22(2):299–305. doi:10.1080/14737167.2021.1945445.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65(9):1141–1148. doi:10.1111/J.1398-9995.2010.02336.X.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM. Omalizumab for severe allergic asthma treatment in italy: a cost-effectiveness analysis from PROXIMA study. Risk Manag Healthc Policy. 2020;13:43–53. doi:10.2147/RMHP.S211321.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–1776. doi:10.1185/030079906X132389.
   PubMed Web of Science ®Google Scholar
• Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17(8):772–782. doi:10.1016/J.JVAL.2014.07.009/ATTACHMENT/43EBCEF0CA7A-427D-A1BFDD0C69FB794E/MMC2.DOCX
   PubMed Web of Science ®Google Scholar
• Levy AN, García A Ruiz AJ, García-Agua Soler N, Sanjuan MVH. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–210. doi:10.3109/02770903.2014.941474.
   PubMed Web of Science ®Google Scholar
• Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36. doi:10.1016/J.VHRI.2013.01.007.
   PubMedGoogle Scholar
• Padilla-Galo A, García-Ruiz AJ, Levy Abitbol RC, Olveira C, Rivas-Ruiz F, García-Agua Soler N, Pérez Morales M, Valencia Azcona B, Tortajada-Goitia B, Moya-Carmona I, et al. Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res. 2021;22(1):163. doi:10.1186/S12931-021-01758-0.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country. Pediatr Pulmonol. 2021;56(9):2987–2996. doi:10.1002/PPUL.25541.
   PubMed Web of Science ®Google Scholar
• Suzuki C, Lopes da Silva N, Kumar P, Pathak P, Ong SH. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–839. doi:10.1080/13696998.2017.1333513.
   PubMed Web of Science ®Google Scholar
• Tan LE, Tan WHG, Aziz MIA, Koh MS, Tay TR, Pearce F, Ng K. Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. J Asthma. 2022;59(1):189–199. doi:10.1080/02770903.2020.1837158/SUPPL_FILE/IJAS_A_1837158_SM5166.DOCX.
   PubMed Web of Science ®Google Scholar
• Wu AC, David Paltiel A, Kuntz KM, Weiss ST, Fuhlbrigge AL, Haven N. Costeffectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. Am Acad Allergy Asthma Immunol. 2007;120(5):1146–1152. doi:10.1016/j.jaci.2007.07.055.
   Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Marra CA, Chen W, Fitzgerald JM. Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS ONE. 2016;11(1):e0146003–15. doi:10.1371/journal.pone.0146003.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sadatsafavi M, Fitzgerald JM. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;16(3):3–8. doi:10.1186/s12962-018-0089-8.
   PubMed Web of Science ®Google Scholar
• Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma. 2020;57(1):87–94. doi:10.1080/02770903.2018.1544642.
   PubMed Web of Science ®Google Scholar
• González-Barcala FJ, Muñoz-Gall X, Mariscal E, García A, Yang S, van de Wetering G, Izquierdo-Alonso JL. Cost-effectiveness analysis of anti–IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874–882. doi:10.1080/13696998.2021.1941065/SUPPL_FILE/IJME_A_1941065_SM4904.DOCX.
   PubMed Web of Science ®Google Scholar
• Tohda Y, Matsumoto H, Miyata M, et al. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2021. doi:10.1080/02770903.2021.1996596/SUPPL_FILE/IJAS_A_1996596_SM3089.DOCX.
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgEmediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216. doi:10.1016/J.JACI.2009.09.021.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh K-M, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/J.1398-9995.2004.00772.X.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi:10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• WebPlotDigitizer. Version 4.4. Published August 15, 2021 [accessed 2022 Jul 21]. https://automeris.io/WebPlotDigitizer/.
   Google Scholar
• Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):513–523. doi:10.1586/14737167.2015.1103185.
   PubMed Web of Science ®Google Scholar
• Veettil SK, Harris J, Syeed MS, Thakkinstian A, Chaikledkaew U, Witt DM, Chaiyakunapruk N. Incremental net monetary benefit of direct oral anticoagulants for the prevention of venous thromboembolism after total knee or hip replacement: a systematic review and meta-analysis. Thromb Res. 2022;216:74–83. doi:10.1016/j.thromres.2022.06.004.
   PubMed Web of Science ®Google Scholar
• Dilokthornsakul P, Lan LM, Thakkinstian A, Hutubessy RCW, Lambach P, Chaiyakunapruk N. Economic evaluation of seasonal influenza vaccination in elderly and healthcare workers: a systematic review and meta-analysis. Electron J. 2021. doi:10.2139/SSRN.3882519.
   Google Scholar
• Bagepally BS, Gurav YK, Anothaisintawee T, Youngkong S, Chaikledkaew U, Thakkinstian A. Cost utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis. Value Health. 2019;22(12):1458–1469. doi:10.1016/J.JVAL.2019.09.2750.
   PubMed Web of Science ®Google Scholar
• Consumer price index 2010. = 100). Bank TW [accessed 2022 Jul 20]. https://data.worldbank.org/indicator/FP.CPI.TOTL?locations=US%E2%89%A4/SEURLD.
   Google Scholar
• PPP conversion factor, private consumption (LCU per international $). Bank TW [accessed 2022 Jul 20]. https://data.worldbank.org/indicator/PA.NUS.PRVT.PP?.
   Google Scholar
• Udayachalerm S, Renouard MG, Anothaisintawee T, Thakkinstian A, Veettil SK, Chaiyakunapruk N. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. J Med Econ. 2022;25(1):26–37. doi:10.1080/13696998.2021.2008195.
   PubMed Web of Science ®Google Scholar
• Bagepally BS, Chaikledkaew U, Gurav YK, Anothaisintawee T, Youngkong S, Chaiyakunapruk N, McEvoy M, Attia J, Thakkinstian A. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diab Res Care. 2020;8(1):e001020. doi:10.1136/bmjdrc-2019-001020.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–145. doi:10.1016/J.CCT.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. WSBJBACMSP doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Jin HJ. Biological treatments for severe asthma. Yeungnam Univ J Med. 2020;37(4):262–268. doi:10.12701/YUJM.2020.00647.
   PubMedGoogle Scholar
• Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann Allergy Asthma Immunol. 2018;121(4):406–413. doi:10.1016/j.anai.2018.07.033.
   PubMed Web of Science ®Google Scholar
• Anderson WC, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372. doi:10.1016/J.ANAI.2019.01.018.
   PubMed Web of Science ®Google Scholar
• Azzano P, Dufresne É, Poder T, Bégin P. Economic considerations on the usage of biologics in the allergy clinic. Allergy. 2021;76(1):191–209. doi:10.1111/all.14494.
   PubMed Web of Science ®Google Scholar
• Doz M, Chouaid C, Com-Ruelle L, Calvo E, Brosa M, Robert J, Decuypère L, Pribil C, Huerta A, Detournay B. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med. 2013;13:15. doi:10.1186/1471-2466-13-15.
   PubMed Web of Science ®Google Scholar
• Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–359. doi:10.1007/s10198-009-0173-2.
   PubMed Web of Science ®Google Scholar
• Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks. Draft Evidence Report Prepared for. Institute for Clinical and Economic Review; 2018.
   Google Scholar
• Diagnosis and Management of Difficult-to-treat & Severe Asthma - Global Initiative for Asthma - GINA. [accessed 2022 Oct 5]. https://ginasthma.org/severeasthma/.
   Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–139. doi:10.1016/J.JVAL.2017.12.007.
   PubMed Web of Science ®Google Scholar